Proportion of patients in remission according to different criteria and biologic class
| Anti-TNF | Tocilizumab | OR (95% CI) | |
|---|---|---|---|
| Overall Population | |||
| DAS28 (n=524) | 102/429 (23.8) | 55/95 (57.9) | 4.4 (2.8–7.0) |
| CDAI (n=327) | 36/260 (13.9) | 14/67 (20.9) | 1.6 (0.8–3.2) |
| SDAI (n=298) | 33/239 (13.8) | 14/59 (23.7) | 1.9 (0.97–3.9) |
| Boolean (n=468) | 42/358 (11.7) | 11/83 (13.3) | 1.1 (0.6–2.3) |
| Biologic-naïve patients | |||
| DAS28 (n=417) | 89/365 (24.4) | 37/52 (71.2) | 7.7 (4.0–14.5) |
| CDAI (n=258) | 33/223 (14.8) | 11/35 (31.4) | 2.6 (1.2–5.8) |
| SDAI (n=237) | 32/206 (15.5) | 11/31 (35.5) | 2.99 (1.33–6.76) |
| Boolean (n=348) | 36/302 (11.9) | 8/46 (17.4) | 1.6 (0.7–3.5) |